Literature DB >> 19766600

Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors.

Stefania Merighi1, Carolina Simioni, Stefania Gessi, Katia Varani, Pier Andrea Borea.   

Abstract

The thermodynamic parameters DeltaG degrees , DeltaH degrees and DeltaS degrees of the binding equilibrium of agonists and antagonists at cannabinoid CB(1) and CB(2) receptors were determined by means of affinity measurements at different temperatures and van't Hoff plots were constructed. Affinity constants were measured on CHO cells transfected with the human CB(1) and CB(2) receptors by inhibition assays of the binding of the cannabinoid receptor agonist [(3)H]-CP-55,940. van't Hoff plots were linear for agonists and antagonists in the temperature range 0-30 degrees C. The thermodynamic parameters for CB(1) receptors fall in the ranges 17< or =DeltaH degrees < or =59 kJ/mol and 213< or =DeltaS degrees < or =361 kJ/mol for agonists and -52< or =DeltaH degrees < or =-26 kJ/mol and -12< or =DeltaS degrees < or =38 kJ/mol for antagonists. The thermodynamic parameters for CB(2) receptors fall in the ranges 27< or =DeltaH degrees < or =48 kJ/mol and 234< or =DeltaS degrees < or =300 kJ/mol for agonists and -19< or =DeltaH degrees < or =-17 kJ/mol and 43< or =DeltaS degrees < or =74 kJ/mol for antagonists. Collectively, these data show that agonist binding is always totally entropy-driven while antagonist binding is enthalpy and entropy-driven, indicating that CB(1) and CB(2) receptors are thermodynamically discriminated. These data could give new details on the nature of the forces driving the CB(1) and CB(2) binding at a molecular level. Enthalpy, entropy, free energy and binding affinity for each ligand to its receptor can all be assessed and therefore the optimal binding profile discovered. Carrying out these binding investigations as early as possible in the discovery process increases the probability that a lead compound will become a successful pharmaceutical compound.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19766600     DOI: 10.1016/j.bcp.2009.09.009

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide.

Authors:  Stefania Merighi; Stefania Gessi; Katia Varani; Carolina Simioni; Debora Fazzi; Prisco Mirandola; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells.

Authors:  Stefania Merighi; Stefania Gessi; Katia Varani; Debora Fazzi; Prisco Mirandola; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

3.  Thermodynamics and docking of agonists to the β(2)-adrenoceptor determined using [(3)H](R,R')-4-methoxyfenoterol as the marker ligand.

Authors:  Lawrence Toll; Karolina Pajak; Anita Plazinska; Krzysztof Jozwiak; Lucita Jimenez; Joseph A Kozocas; Mary J Tanga; James E Bupp; Irving W Wainer
Journal:  Mol Pharmacol       Date:  2012-03-20       Impact factor: 4.436

4.  The effect of stereochemistry on the thermodynamic characteristics of the binding of fenoterol stereoisomers to the beta(2)-adrenoceptor.

Authors:  Krzysztof Jozwiak; Lawrence Toll; Lucita Jimenez; Anthony Yiu-Ho Woo; Rui-Ping Xiao; Irving W Wainer
Journal:  Biochem Pharmacol       Date:  2010-02-06       Impact factor: 5.858

5.  Development and characterization of immobilized cannabinoid receptor (CB1/CB2) open tubular column for on-line screening.

Authors:  R Moaddel; A Rosenberg; K Spelman; J Frazier; C Frazier; S Nocerino; A Brizzi; C Mugnaini; I W Wainer
Journal:  Anal Biochem       Date:  2011-01-06       Impact factor: 3.365

6.  Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes.

Authors:  Gemma Navarro; Katia Varani; Irene Reyes-Resina; Verónica Sánchez de Medina; Rafael Rivas-Santisteban; Carolina Sánchez-Carnerero Callado; Fabrizio Vincenzi; Salvatore Casano; Carlos Ferreiro-Vera; Enric I Canela; Pier Andrea Borea; Xavier Nadal; Rafael Franco
Journal:  Front Pharmacol       Date:  2018-06-21       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.